Russia says its Sputnik V COVID-19 vaccine is 92% effective
News Line
Ukraine reports 5,276 new COVID-19 cases Zelensky: Every third Ukrainian considers road construction one of greatest achievements of 2021 Ukraine ready to implement Minsk agreements, but Russia's desire needed - Yermak Michel: EU unanimously agree to roll over economic sanctions against Russia Actions by Ukraine's partners will help prevent worst-case scenario - Zelensky COVID-19 in Ukraine: Health officials confirm 8,899 daily cases as of Dec 17 Macron tells Zelensky he declared support for Ukraine in call with Putin Zelensky, Scholz discuss gas transit through Ukraine after 2024 Ukraine ready for any format of talks with Russia - Zelensky Ukraine’s only journalist in Russia facing extremism charges - lawyer PM Shmyhal: First two applications for investment projects worth $96 million filed Zelensky, PM of Italy discuss security situation around Ukraine President signs off State Budget 2022 London considering all options for responding to Russia's aggression against Ukraine Putin, Biden to hold another round of talks Some 260,000 Ukrainians “victims of human trafficking” over 30 years - prosecutor general Ukraine plans to create center to protect energy infrastructure from cyber attacks No clear idea so far when Normandy Four top diplomats set to meet - German Ambassador Ukraine receives EUR 600M in macro-financial assistance from EU Zelensky holds phone conversation with PM of Israel Ukraine sets new daily COVID vaccination record MFA: European Union has not yet removed Ukraine from list of safe countries Kyiv records 1,023 new COVID-19 cases, 29 deaths G7 ambassadors welcome adoption of law on NABU status Ukraine can increase Covid vaccination rates to 1.5M a week – Liashko

Russia’s Sputnik V vaccine is 92% effective at protecting people from COVID-19 according to interim trial results, the country’s sovereign wealth fund said on Wednesday, as Moscow rushes to keep pace with Western drugmakers in the race for a shot.

The initial results are only the second to be published from a late-stage human trial in the global effort to produce vaccines that could halt a pandemic that has killed more than 1.2 million people and ravaged the world economy.

Russia registered its COVID-19 vaccine for public use in August, the first country to do so, though the approval came before the start of the large-scale trial in September.

“We are showing, based on the data, that we have a very effective vaccine,” said RDIF head Kirill Dmitriev, adding that it was the sort of news that the vaccine’s developers would talk about one day with their grandchildren.

The interim results are based on data from the first 16,000 trial participants to receive both shots of the two-dose vaccine, the Russian Direct Investment Fund (RDIF), which has been backing the vaccine and marketing it globally, said.

The interim analysis was conducted after 20 participants in the trial developed COVID-19 and examined how many had received the vaccine versus a placebo.

That is significantly lower than the 94 infections in the trial of a vaccine being developed by Pfizer Inc PFE.N and BioNTech. To confirm the efficacy rate, Pfizer said it would continue its trial until there were 164 COVID-19 cases.

The Russian trial will continue for six more months, RDIF said in a statement, and data from the trial will also be published in a leading international medical journal following a peer review.